Thursday, May 11, 2017  |  Volume 9 / Number 10  |  A Production of the BioProcessing Journal
ISBioTech 5th Fall Meeting
Career Development
CMC Strategy Forum Europe
May 22–24, 2017
Killarney, Ireland
CMC Strategy Forum Summer
July 17–18, 2017
Gaithersburg, Maryland USA
25th ESACT Meeting
25th ESACT Meeting
May 14–17, 2017
Lausanne, Switzerland
ESACT Courses:
Cell Culture-Based Viral Vaccines Course – Second Edition
September 19–22, 2017
Animal Cell Technology Course 2017 – Seventh Edition
September 24–28, 2017
Llafranc, Costa Brava, Spain
30th International Symposium on Preparative and Process Chromatography
July 16–19, 2017
Philadelphia, Pennsylvania USA
XXV Anniversary Congress
October 17–20, 2017
Berlin, Germany
ISBioTech 8th Spring Meeting
Suggested Reading
Identification of Worst-Case Model Viruses
for Low and High pH Inactivation
By Raymond Nims, PhD, RMC Pharmaceutical Solutions, Inc., S. Steve Zhou, PhD, Microbac Laboratories, Inc., and Mark Plavsic, PhD, DVM Lysogene
Discuss on LinkedIn
Products & Services
Biobank Data Management System with Built-In Data Visualization Capabilities
Brooks Life Science Systems (Brooks) is launching its newest informatics platform, BioStudies™, to provide the industry's most comprehensive purpose-built sample intelligence software system integrated with enterprise analytics and mobility software from MicroStrategy® Incorporated. This new solution includes innovative visualization and dashboard capabilities to support global sharing of biobank sample data and advance the optimization of biological samples for research purposes.
Designed specifically to integrate global sample inventory data, BioStudies is a robust, user configurable solution that connects sample inventory information with consent, phenotypic, and clinical data, giving customers a single tool to manage sample collections within population and research-based studies. Further, BioStudies enables improved sample lifecycle management of valuable samples from collection through manifesting, receipt, storage, analysis, and disposal. BioStudies can also integrate data from Brooks' automated biostores, instruments, and equipment, giving researchers a single, cohesive sample data management solution. For more information, please visit
Commercial-Ready Gene Therapy Supply for the Industry

Brammer Bio ("Brammer"), a contract development and manufacturing organization (CDMO), now offers a complete range of process development, clinical phase, and Current Good Manufacturing Practices (CGMP) services for cell and gene therapies using multiple platform technologies.

Brammer is on-track to complete the establishment of commercial-ready gene therapy manufacturing capacity in Cambridge, Massachusetts in the second half of 2017. This follows the January 1, 2017 acquisition of Biogen's 66,000 sq ft biologics manufacturing facility in Cambridge and 49,000 sq ft state-of-the-art distribution and warehousing facility in Somerville, Massachusetts, including the on-boarding of an experienced team of 100 employees. Originally built for the manufacture of Biogen's clinical and commercial biologics, Brammer is renovating the Cambridge facility for late-stage clinical development and commercial launch of gene therapy products.

Since completing a merger with Florida Biologix in March 2016, Brammer has doubled its capacity for process development and is also expanding its clinical production space in Alachua, Florida. Brammer previously announced plans to build-out its 50,000 sq ft facility in Lexington, Massachusetts, which is currently being designed for late-stage and commercial cell therapy supply. For more information, please visit

New NK (V158+) Cells Optimized for ADCC Assays Online

ReachBio Research Labs (ReachBio LLC), a contract research organization (CRO) specializing in primary cell assay services and products, now offers sourced, enriched, and tested primary natural killer (NK) cells from normal and healthy donors to facilitate better antibody research through antibody-dependent cell-mediated cytotoxicity (ADCC) assays.

NK (V158+) Cells
The ability of NK cells to bind monoclonal antibodies (mAbs) that selectively target tumor cells for killing is considered important to the efficacy of the therapeutic mAb in ADCC assays. In various oncology clinical studies using IgG1 isotype therapeutic mAbs, different outcomes were observed with some of the findings believed to be related to the numbers and functional activity of the patient NK cell population. Supporting studies have shown that NK cells derived from donors that display a specific polymorphism of the CD 16 Fc gamma receptor (homozygous for FCGR3A with valine at position 158) bound significantly more IgG1, and hence those NK cells were rendered more 'active' compared with cells from donors who were homozygous for that receptor with phenylalanine at the same position. Thus, using NK cells with this V158 polymorphism (V158+) results in a more 'active' effector cell that triggers a more robust cytotoxic response in ADCC assays. For more information, please visit
Job Posting
indee labs
Email Cover Letter and CV to:
Career Development
ISPPP 2017
July 19–21, 2017
Philadelphia, Pennsylvania USA
13th Conference on Protein Expression in Animal Cells
September 24–28, 2017
Valencia, Spain
BPJ Publishing
BioProcessing Journal Open Access
Techno-Blast Masthead

Courtesy of © 2014 Lonza Group, Ltd., Basel, Switzerland
Economize by combining Techno-Blast and BioProcessing Journal advertising into one package.

Request a media kit today!
Did a colleague forward this to you? Subscribe here. While we'd hate to see you go, you can unsubscribe instantly.